Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006262 · ClinicalTrials.gov registry record · Phase 2
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00006262 is a Phase 2 study that was terminated before completion, run by Northwestern University.
The verdict
NCT00006262, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have refractory stage III or stage IV ovarian epithelial cancer.
Interventions
- DRUG becatecarin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006262
The ClinicalTrials.gov registry entry for NCT00006262 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which becatecarin is the first listed.
NCT00006262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006262 about?
NCT00006262 is a clinical study titled "Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have refractory stage III or stage IV ovarian epithelial cancer.
What is the current status of trial NCT00006262?
This trial is currently terminated. It is a Phase 2 study. The study started on 2000-07. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00006262?
The interventions under investigation include: becatecarin (DRUG).
Who is sponsoring clinical trial NCT00006262?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.